MOPEAD coordinates survey on GP attitudes to Alzheimer's disease treatment across five European countries

 

The MOPEAD Project has coordinated a large scale anonymous survey on General Practitioners' (GP) attitudes towards the early diagnosis of Alzheimer's disease (AD) and the availability of current treatments. 

 

The survey aims to get a better understanding of how GP's handle the diagnosis of mild cognitive impairment (MCI) or dementia and how useful it is to make such a diagnosis in a more timely manner. 

 

With over 200 responses so far from over 5 different European countries including Spain, Sweden, The Netherlands, Slovenia and Germany, the survey will support MOPEAD's aim to move the AD environment towards earlier diagnosis. Currently only 40-50% of people living with dementia will have received a diagnosis. An earlier diagnosis would provide an opportunity for intervention giving people with Alzheimer's disease and their families "more time" and the potential for inclusion in Clinical Trails.[1]

 

We hope the survey will highlight what GP's need from policy makers to deliver a step-change in how public health services provide timely diagnosis and support to those suffering from Alzheimer's disease, a figure which is expected to rise to 131 million world wide by 2050.[2]

 

You can read more about Alzheimer's disease on our website here: https://www.mopead.eu/support.

 

Or check out our infographics created by our MOPEAD team of experts to guide you through your memory health: https://www.mopead.eu/infographics 

 

 

[1] World Alzheimer Report 2016: https://www.alz.co.uk/research/WorldAlzheimerReport2011.pdf 

 

[2]UN Dept of Economic and Social Affairs: https://esa.un.org/unpd/wpp/DataQuery/  

Share on Facebook
Share on Twitter
Please reload

Please reload

Archive
Please reload

Search By Tags
Please reload

Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

©2018 MOPEAD

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations